Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

AIDA: Allergy Immunotherapy based on Designed Allergens

Project description

A faster, more effective allergy treatment

Allergies are a major global health concern, with respiratory and food allergies affecting 30 % and 10 % of the population, respectively. Many sufferers experience both due to structural similarities between pollen and food allergens. Current treatments focus on symptom relief, which is expensive and inconvenient, while allergen immunotherapy (AIT) remains the only curative option. However, AIT requires years of treatment, has inconsistent efficacy, and is costly for both patients and healthcare systems. The ERC-funded AIDA project aims to revolutionise AIT by developing a therapy that treats multiple allergies simultaneously, accelerates immune tolerance, and minimises side effects. This approach could improve patient outcomes and make allergy treatment more effective and accessible.

Objective

Allergy is a severe immune reaction to foreign substances known as allergens, with respiratory and food allergies affecting 30% and 10% of the global population, respectively. A high structural similarity exists between pollen and food allergens. Therefore, many people suffer from both types of allergies. Untreated allergies have detrimental effects on health-related quality of life, family economics, and work attendance. Allergy is treated as a chronic disease, with a focus on reducing symptoms (e.g. antihistamines), which is cumbersome and expensive. The only existing curative treatment, allergen immunotherapy (AIT), consists of up to 5 years of monthly exposure to low amounts of the triggering allergen until the immune system is desensitized. Unfortunately, this approach is costly for healthcare providers and its efficacy varies, being especially low for patients allergic to multiple pollen and foodstuff sources. Only 40% of patients choose to undergo AIT, and 20% of these terminate the treatment early due to strong side effects or lack of efficacy. We propose the development of an urgently needed AIT by treating several allergies at once, achieving tolerance faster, and reducing side effects.

Fields of science (EuroSciVoc)

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC-POC - HORIZON ERC Proof of Concept Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2022-POC2

See all projects funded under this call

Host institution

DANMARKS TEKNISKE UNIVERSITET
Net EU contribution
€ 150 000,00
Address
ANKER ENGELUNDS VEJ 101
2800 Kongens Lyngby
Denmark
Region
Danmark Hovedstaden Københavns omegn
Activity type
Higher or Secondary Education Establishments
Links
Total cost
No data

Beneficiaries (1)